Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

Abstract In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) recei...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Alcaraz, Alfredo Rodríguez-Antolín, Joaquín Carballido-Rodríguez, David Castro-Díaz, José Medina-Polo, Jesús M. Fernández-Gómez, Vincenzo Ficarra, Joan Palou, Javier Ponce de León Roca, Javier C. Angulo, Manuel Esteban-Fuertes, José M. Cózar-Olmo, Noemí Pérez-León, José M. Molero-García, Antonio Fernández-Pro Ledesma, Francisco J. Brenes-Bermúdez, José Manasanch
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dbfb0dfd6b60488a9466f0e9d3128226
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbfb0dfd6b60488a9466f0e9d3128226
record_format	dspace
spelling	oai:doaj.org-article:dbfb0dfd6b60488a9466f0e9d31282262021-12-02T19:16:47ZEfficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients10.1038/s41598-021-98586-52045-2322https://doaj.org/article/dbfb0dfd6b60488a9466f0e9d31282262021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98586-5https://doaj.org/toc/2045-2322Abstract In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.4 mg/day) or the hexanic extract of Serenoa repens (HESr, 320 mg/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6 months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (p = 0.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; p < 0.001), particularly ejaculation dysfunction and orthostatic hypotension. These results show that HESr is a valid treatment option for men with moderate/severe LUTS/BPH; improvements in urinary symptoms and QoL were similar to those observed for tamsulosin, but with considerably fewer adverse effects.Antonio AlcarazAlfredo Rodríguez-AntolínJoaquín Carballido-RodríguezDavid Castro-DíazJosé Medina-PoloJesús M. Fernández-GómezVincenzo FicarraJoan PalouJavier Ponce de León RocaJavier C. AnguloManuel Esteban-FuertesJosé M. Cózar-OlmoNoemí Pérez-LeónJosé M. Molero-GarcíaAntonio Fernández-Pro LedesmaFrancisco J. Brenes-BermúdezJosé ManasanchNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Antonio Alcaraz Alfredo Rodríguez-Antolín Joaquín Carballido-Rodríguez David Castro-Díaz José Medina-Polo Jesús M. Fernández-Gómez Vincenzo Ficarra Joan Palou Javier Ponce de León Roca Javier C. Angulo Manuel Esteban-Fuertes José M. Cózar-Olmo Noemí Pérez-León José M. Molero-García Antonio Fernández-Pro Ledesma Francisco J. Brenes-Bermúdez José Manasanch Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
description	Abstract In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.4 mg/day) or the hexanic extract of Serenoa repens (HESr, 320 mg/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6 months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (p = 0.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; p < 0.001), particularly ejaculation dysfunction and orthostatic hypotension. These results show that HESr is a valid treatment option for men with moderate/severe LUTS/BPH; improvements in urinary symptoms and QoL were similar to those observed for tamsulosin, but with considerably fewer adverse effects.
format	article
author	Antonio Alcaraz Alfredo Rodríguez-Antolín Joaquín Carballido-Rodríguez David Castro-Díaz José Medina-Polo Jesús M. Fernández-Gómez Vincenzo Ficarra Joan Palou Javier Ponce de León Roca Javier C. Angulo Manuel Esteban-Fuertes José M. Cózar-Olmo Noemí Pérez-León José M. Molero-García Antonio Fernández-Pro Ledesma Francisco J. Brenes-Bermúdez José Manasanch
author_facet	Antonio Alcaraz Alfredo Rodríguez-Antolín Joaquín Carballido-Rodríguez David Castro-Díaz José Medina-Polo Jesús M. Fernández-Gómez Vincenzo Ficarra Joan Palou Javier Ponce de León Roca Javier C. Angulo Manuel Esteban-Fuertes José M. Cózar-Olmo Noemí Pérez-León José M. Molero-García Antonio Fernández-Pro Ledesma Francisco J. Brenes-Bermúdez José Manasanch
author_sort	Antonio Alcaraz
title	Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
title_short	Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
title_full	Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
title_fullStr	Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
title_full_unstemmed	Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
title_sort	efficacy and tolerability of the hexanic extract of serenoa repens compared to tamsulosin in moderate-severe luts-bph patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dbfb0dfd6b60488a9466f0e9d3128226
work_keys_str_mv	AT antonioalcaraz efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT alfredorodriguezantolin efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT joaquincarballidorodriguez efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT davidcastrodiaz efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT josemedinapolo efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT jesusmfernandezgomez efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT vincenzoficarra efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT joanpalou efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT javierponcedeleonroca efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT javiercangulo efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT manuelestebanfuertes efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT josemcozarolmo efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT noemiperezleon efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT josemmolerogarcia efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT antoniofernandezproledesma efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT franciscojbrenesbermudez efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients AT josemanasanch efficacyandtolerabilityofthehexanicextractofserenoarepenscomparedtotamsulosininmoderateseverelutsbphpatients
_version_	1718376942947794944

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

Ejemplares similares